27378175|t|Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery
27378175|a|For marginally operable stage IIIA non-small-cell lung cancer (NSCLC), surgery might not be done as planned after neoadjuvant concurrent chemoradiotherapy (CCRT) for reasons (unresectable or medically inoperable conditions, or patient refusal). This study aims to investigate the outcomes of a phased CCRT protocol established to maximize the operability of marginally operable stage IIIA NSCLC and to care for reassessed inoperable patients, in comparison with continuous-course definitive CCRT. Forty-seven patients with marginally operable stage IIIA NSCLC receiving CCRT were included. Twenty-eight patients were treated with our phased CCRT protocol, including neoadjuvant CCRT followed by surgery (group A, n = 16) or, for reassessed inoperable patients, maintenance chemotherapy and split-course CCRT boost (group B, n = 12). The other 19 were treated with continuous-course definitive CCRT (group C). Overall survival (OS) and progression-free survival (PFS) were analyzed. Among all, median OS and PFS were 35.6 and 12.8 months, respectively (median follow-up, 22.3 months). The median OS of group A (not reached) was better than that of group B (34.4 months) and group C (15.2 months) (P = .009). On multivariate analysis, performance status 0 to 1 (hazard ratio [HR], 0.026; P < .001), adenocarcinoma (HR, 0.156; P = .003), and group A (HR, 0.199; P = .033) were independent prognostic factors. The OS of group B (HR, 0.450; 95% confidence interval, 0.118-1.717; P = .243) was not statistically different from that of group C. For marginally operable stage IIIA NSCLC, our phased CCRT strategy may optimize survival by maximizing operability and maintain an acceptable survival for reassessed inoperable patients by split-course CCRT boost following maintenance chemotherapy.
27378175	0	10	Optimizing	T052	C2698650
27378175	11	19	Survival	T169	C0220921
27378175	23	31	Patients	T101	C0030705
27378175	37	56	Marginally Operable	T080	C0205188
27378175	57	94	Stage IIIA Non-Small-Cell Lung Cancer	T191	C0278983
27378175	105	122	Chemoradiotherapy	T061	C0436307
27378175	123	127	With	T169	C0038895
27378175	131	138	Without	T080	C0332288
27378175	139	146	Surgery	T169	C0038895
27378175	151	170	marginally operable	T080	C0205188
27378175	171	208	stage IIIA non-small-cell lung cancer	T191	C0278983
27378175	210	215	NSCLC	T191	C0278983
27378175	218	225	surgery	T169	C0038895
27378175	261	272	neoadjuvant	T061	C0600558
27378175	273	301	concurrent chemoradiotherapy	T061	C3178775
27378175	303	307	CCRT	T061	C3178775
27378175	322	334	unresectable	T201	C1519810
27378175	338	358	medically inoperable	T080	C0205187
27378175	359	369	conditions	T080	C0348080
27378175	374	389	patient refusal	T055	C0040809
27378175	397	402	study	T062	C2603343
27378175	411	422	investigate	T169	C1292732
27378175	427	435	outcomes	T169	C1274040
27378175	441	461	phased CCRT protocol	T061	C0040808
27378175	490	501	operability	T169	C0205245
27378175	505	524	marginally operable	T080	C0205188
27378175	525	541	stage IIIA NSCLC	T191	C0278983
27378175	558	568	reassessed	T052	C1516048
27378175	569	588	inoperable patients	T101	C0030705
27378175	609	642	continuous-course definitive CCRT	T061	C3178775
27378175	656	664	patients	T101	C0030705
27378175	670	689	marginally operable	T080	C0205188
27378175	690	706	stage IIIA NSCLC	T191	C0278983
27378175	717	721	CCRT	T061	C3178775
27378175	750	758	patients	T101	C0030705
27378175	764	771	treated	T169	C1522326
27378175	781	801	phased CCRT protocol	T061	C0040808
27378175	813	824	neoadjuvant	T061	C0600558
27378175	825	829	CCRT	T061	C3178775
27378175	842	849	surgery	T169	C0038895
27378175	851	858	group A	T078	C0441833
27378175	876	886	reassessed	T052	C1516048
27378175	887	906	inoperable patients	T101	C0030705
27378175	898	906	patients	T101	C0030705
27378175	908	932	maintenance chemotherapy	T033	C0481504
27378175	937	954	split-course CCRT	T061	C3178775
27378175	955	960	boost	T169	C1511253
27378175	962	969	group B	T078	C0441833
27378175	998	1005	treated	T169	C1522326
27378175	1011	1044	continuous-course definitive CCRT	T061	C3178775
27378175	1046	1053	group C	T078	C0441833
27378175	1056	1072	Overall survival	T081	C4086681
27378175	1074	1076	OS	T081	C4086681
27378175	1082	1107	progression-free survival	T081	C0242792
27378175	1109	1112	PFS	T081	C0242792
27378175	1119	1127	analyzed	T062	C0936012
27378175	1140	1146	median	T081	C0876920
27378175	1147	1149	OS	T081	C4086681
27378175	1154	1157	PFS	T081	C0242792
27378175	1177	1183	months	T079	C0439231
27378175	1199	1205	median	T081	C0876920
27378175	1206	1215	follow-up	T058	C1522577
27378175	1222	1228	months	T079	C0439231
27378175	1235	1241	median	T081	C0876920
27378175	1242	1244	OS	T081	C4086681
27378175	1248	1255	group A	T078	C0441833
27378175	1294	1301	group B	T078	C0441833
27378175	1308	1314	months	T079	C0439231
27378175	1320	1327	group C	T078	C0441833
27378175	1334	1340	months	T079	C0439231
27378175	1357	1378	multivariate analysis	T081	C0026777
27378175	1380	1398	performance status	T201	C1518965
27378175	1407	1419	hazard ratio	T081	C2985465
27378175	1421	1423	HR	T081	C2985465
27378175	1444	1458	adenocarcinoma	T191	C0001418
27378175	1460	1462	HR	T081	C2985465
27378175	1486	1493	group A	T078	C0441833
27378175	1495	1497	HR	T081	C2985465
27378175	1521	1551	independent prognostic factors	T201	C1514474
27378175	1557	1559	OS	T081	C4086681
27378175	1563	1570	group B	T078	C0441833
27378175	1572	1574	HR	T081	C2985465
27378175	1587	1606	confidence interval	T081	C0009667
27378175	1639	1662	statistically different	T080	C1705242
27378175	1676	1683	group C	T078	C0441833
27378175	1689	1708	marginally operable	T080	C0205188
27378175	1709	1725	stage IIIA NSCLC	T191	C0278983
27378175	1731	1751	phased CCRT strategy	T061	C0040808
27378175	1756	1764	optimize	T052	C2698650
27378175	1765	1773	survival	T169	C0220921
27378175	1788	1799	operability	T169	C0205245
27378175	1827	1835	survival	T169	C0220921
27378175	1840	1850	reassessed	T052	C1516048
27378175	1851	1870	inoperable patients	T101	C0030705
27378175	1874	1891	split-course CCRT	T061	C3178775
27378175	1892	1897	boost	T169	C1511253
27378175	1908	1932	maintenance chemotherapy	T033	C0481504